University of Kentucky

UKnowledge
Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

6-11-2002

Morphine-6-Sulfate Analogues and Their Use for the Treatment of
Pain
Peter A. Crooks
University of Kentucky, pcrooks@uky.edu

Abdulghani A. Houdi
University of Kentucky

Santosh G. Kottayil
University of Kentucky

D. Allan Butterfield
University of Kentucky, david.butterfield@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Crooks, Peter A.; Houdi, Abdulghani A.; Kottayil, Santosh G.; and Butterfield, D. Allan, "Morphine-6-Sulfate
Analogues and Their Use for the Treatment of Pain" (2002). Pharmaceutical Sciences Faculty Patents. 81.
https://uknowledge.uky.edu/ps_patents/81

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been
accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

US006403602B1

(12)

(54)

United States Patent

(10) Patent N0.:

Crooks et a1.

(45) Date of Patent:

MORPHINE-6-SULFATE ANALOGUES AND
THEIR USE FOR THE TREATMENT OF

5,629,011 A
5,739,145 A

PAIN

*
*

US 6,403,602 B1
*Jun. 11, 2002

5/1997 Illum ....................... .. 424/434
4/1998 Nagase ..................... .. 514/282

OTHER PUBLICATIONS

(75) Inventors: Peter A- CI‘OOkS; Abdulghani AHOlldi, both of LeXiHgIOH, KY (Us);
SaIltOSh G- Kottayil, Schaurnburg, IL
(Us); D- Allen Buttel‘?eld, LeXingten,
KY (Us)

Beilstein, abstract registry No. 73 97 281, 1995*
Sankyo, Chem. Abstr. vol. 96 Entry 218088, 1982.*
Brock et al., Chem. Abstr. vol. 124 Entry 161029, 1996.*
Aceto et a1. Chem. Abstr vol. 125 entry 104826, 1995*
Jacobson Chem. Abstr vol. 125 Entry 185591, 1996.*

(73) Assignee The University Of Kentucky Research
Foundatiom Lexingtom KY (Us)

Aceto et a1 Chem Abstr vol. 125 Entry 185593, 1995*
Houdi et al., “3—O—Acetylmorphine—60—Su1fate: A Potent,

Woods et a1. Chem. Abstr. vol. 125 Entry 185592, 1996.*

*

_

_

( ) Nonce:

_

_

Centrally Acting Morphine Derivative”, Pharmacology Bio

Th1s_ patent {ssufzd on a Con?rmed pros‘
ecut1on application ?led under 37 CFR

1996

1'53(d)> and 1S Subleq to the twenty year

Choonara et al., “Morphine Sulphation in Children”, citied

patent term provlslons of 35 USC‘

in Journal of Clinical Pharmacology, Dec. 1990, pp.

154(21)(2)~

897—900. (see Abstract).

_

_

_

_

Sulfate Conjugate at 6—Position of N—Substituted Normor

Patent 15 extended or adlusted under 35

phine Derivatives, cited in Chemical Pharmaceutical Bulle

U'S'C' 154(k)) by 0 days‘

tin”, Aug. 1991, vol. 39, No. 8, pp. 2000—4. (see Abstract).
BroWn et al., “Analgesic Potencies of Morphine 3— and
6—Sulfates After Intracerabroventricular Administration in

Mice: Relationship to Structural Characteristics De?ned by
Mass Spectrometry and Nuclear Magnetic Reseonance”,
Journal of Pharmaceutical Science, vol. 74, No. 8, pp.
821—824, Aug. 1985.

Related US Application Data

(51)

Continuation of application No. 08/881,288, ?led on Jun.

Oguri et al., “Potentiation of Physical Dependence by Con

24, 1997, now abandoned, which is a continuation-in-part of
application No. 08/803,312, ?led on Feb. 20, 1997, now

jugation at the 6—Position 0f Nalorphine”, cited in European
Journal of Pharmacology, Jul_ 1984, VOL 102 NO_ 2, pp

abandoned‘

229—35 (see Abstract).

Int. Cl.7 ....................... .. A61K 31/44; A61P 25/04;

C07D 489/00
(52)

Hirano et al., “Synthesis and Pharmacological Activity of

Sub]eCt_tO any dlsclalmer’, the term of thls

(21) Appl' N05 09/040,240
(22) Filed:
Dec_ 31’ 1997

(63)

chemistry and Behavior, vol. 53, No. 3, pp. 665—671, Mar.

US. Cl. ........................................ .. 514/282; 546/44
of Search ........................... ..

(56)

References Cited

A
A
A
A

12/1982
1/1985
6/1993
11/1993

Portoghese ................ ..
Bodor .................... ..
Kanematsu et a1. ........ ..
Heiman et a1. ............. ..

_

_

cited by eXammer
Primary Examiner_Brenda Coleman
Attorney) Agent) Or Firm_MCDermO[t,

(57)

& Emery

ABSTRACT

3-O-Acetylmorphine-6-sulfate analogues are potent,
centrally-acting morphine derivatives. The compounds are

U.S. PATENT DOCUMENTS
4,362,870
4,496,570
5,219,861
5,258,512

*

546/44
546/15
546/44
546/44

useful for the treatment of pain.

10 Claims, 16 Drawing Sheets

U.S. Patent

Jun. 11,2002

Sheet 2 0f 16

52 2 2

US 6,403,602 B1

Q

$26
5
w///q-\
|

w§8%:
o:A3
mczmw
r
6*w
1+
6l ol

8w
$326v

0mm
2.x0%2:of3o8

W5352

Own
_
._
__
.b
_._

H8235522E3 .2552

c9%2693.
E
IW w

d8r

W
-3

21
%-

U.S. Patent

Jun. 11,2002

A33%32.2 80:538:2;.2 92‘
i25%

8%:
52: €m2? i

Sheet 3 0f 16

US 6,403,602 B1

€2 5:2

of

.wI
m

esuodsea a|qgssod umwgxew %

U.S. Patent

Jun. 11,2002

Sheet 4 0f 16

FIG. 4

H 075

NI

505

124|350

3V02M Sm ve mi
6S5.0 Dhrl

kg e

_ 2O1

TIME (MIN)

US 6,403,602 B1

U.S. Patent

Jun. 11, 2002

Sheet 5 6f 16

FIG. 5

30 T.

5

NIH 10773 SDS

+ Vehicle

cf

25—_

—E)— 2-5 mg/kg

2

:

—I— 10.0 mg/kg

0

-

c7)
__l

20':

<

-

Ea:

15 —

O

..

:

I
C

_

g
LU

_
10 -

z
|-—

_

5

D

_

5

2

_

D

-

O

..

0

US 6,403,602 B1

U.S. Patent

Jun. 11,2002

Sheet 7 0110

US 6,403,602 B1

FIG. 7

-—13-- Morphine

U.S. Patent

Jun. 11,2002

Sheet 8 0f 16

US 6,403,602 B1

FIG. 8

1001

80~

60

%MPA

00+
20“

I

0

100

l

200

Time (min)

300

400

U.S. Patent

Jun. 11, 2002

Sheet 9 0f 16

US 6,403,602 B1

FIG. 9

—cr— Morphine
——-I—— M3Pr6S

%MPA

U.S. Patent

Jun. 11,2002

Sheet 10 0f 16

US 6,403,602 B1

FIG. 10

—D-— Morphine

%MPA

—I—

I

O

100

I

200

Time (min)

300

400

M31bu6S

U.S. Patent

Jun. 11,2002

Sheet 11 0f 16

US 6,403,602 B1

FIG. 11
(PRIOR ART)
100-1

80'

6O _

—C1—

E

Morphine

—l—— M3P6S

2

°\O

40 w

20 -

O

O

|

_|

|

100

200

300

Time (min)

1

400

U.S. Patent

Jun. 11, 2002

Sheet 12 0f 16

US 6,403,602 B1

FIG. 12
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MORPHINE-6-SULFATE ANALOGUES AND
THEIR USE FOR THE TREATMENT OF
PAIN

overcomes de?ciencies in the prior art in providing neW and
effective treatments for pain, and other conditions Whose
symptoms are knoWn to be alleviated With morphine com

pounds.

RELATED APPLICATIONS

This application is a continuation of application Ser. No.

DISCLOSURE OF THE INVENTION

08/881,288 ?led Jun. 24, 1997 noW abandoned: Which is a

continuation-in-part of application Ser. No. 08/803,312,

The present invention relates to morphine analogues,

?led Feb. 20, 1997 noW abandoned.
10

Technical Field

The present invention relates to 3-O-Acetylmorphine-6

More particularly the compounds selected from the group
consisting of the folloWing formulas I and II:

sulfate compounds and their ester derivatives Which are

potent, centrally-acting morphine derivatives. The com
pounds are useful for the treatment of pain.

substituted With both a sulfate group at position siX of the
ring and an ester group at position three. The compounds are
used as analgesics and for the treatment of pain.

15
Formula I

BACKGROUND ART

The opiate analgesic morphine, When administered to
humans, is converted by the liver into three major

metabolites, viZ. morphine-3-O-glucuronide (M3G),
morphine-6-O-glucuronide (M6G) and morphine-3-O
sulfate (M3S) [9,19]. M6G is found in the systemic circu
lation in concentrations exceeding those of morphine itself,
after both parenteral [12,19] and oral administration [12,18].
M6G is a very potent p-receptor agonist [3] With a high
af?nity for both mu1 and mu2 receptors [1,14] and appears

20

25

X

05036

to cross the blood-brain barrier in spite of its high polarity

compared to morphine [20].
Some morphine compounds are knoWn in the art. For
example, US. Pat. No. 5,219,861 to Kanematsu et al. relates
to a novel morphine-6-thiol derivatives. Kanematsu dis

Wherein X is selected from the group consisting of
30

—OR2,

closes acetylthio-derivatives on the siX position of morphine
and esters on position three.
US. Pat. Nos. 4,496,570 to Bodor and 5,352,680 to 35

OC—R3,

Portoghese et al. relates to opiates With heterocyclic sub
stituents bound to position siX of the opiate ring. Both
patents disclose thiol ring substituents on morphine.

and

US. Pat. No. 4,362,870 to Portoghese relates to a non

addictive analgesic opiate. Portoghese further discloses
morphine-like opiates Which have substituted isothiocyanate

40

groups on position siX and ester groups on position three of
Wherein R1 may be a straight or branched chain alkyl or

the opiate.

alkenyl group having 1—5 carbon atoms;

US. Pat. No. 5,258,512 to Heiman et al. relates to a

method for a ?uorescence polariZation immunoassay proce
dure for determining the amount opiate alkaloids in ?uids.
The invention discloses, in FIG. 13-9, the use of a morphine
sulfonamide on position siX.
Houdi et al., PharmacoL, Biochem. & Behavior (March,

45

Wherein R2 is an alkyl having 1—3 carbon atoms, and
Wherein R3 is H or n-alkyl or branched alkyl With 1—10

carbon atoms (preferably 4—8 carbon atoms),
cycloalkyl, aralkyl, n-alkenyl or branched alkenyl
With 1—10 carbon atoms, and n-alkynyl or branched
alkynyl With 1—10 carbon atoms. R3 is preferably

1996) disclosing morphine-6-sulfate esters and their anal
gesic character. This is the Work of the present inventors.
BroWn et al., J. Pharm. Sci. 74:821—24 (August, 1985)
relates to the analgesic potencies of several morphine ana
logues With covalent modi?cations at carbons 3 and 6.

Speci?cally, morphine-6-sulfate is disclosed.

OCH3, OCOCH3, OCOCH2CH3, OCOCH(CH3)2,
OCOCH(CH3)3 and OCO-phenyl.
Formula II

55

Choonara et al., J. Clin. Pharmacol. 30:897—900

(December, 1990) describes the metabolism of morphine
and the detection of morphine-3 and morphine-6-sulfate.
Oguri et al., Eur J. Pharmacol. 102:229—35 (July, 1984)
relates to the dependency of nalorphine-6-sulfate conju

60

gates.
Hirano et al., Chem. Pharm. Bull. 39:2000—4 (August,

X

1991) relates to the synthesis and pharmacological activity

of nalorphine-6-sulfate conjugates.
There is a need in the art for effective treatments for

relieving pain in animals and humans. The present invention

05036

65

Wherein X is selected from the group consisting of

—OR2,

US 6,403,602 B1
4
after administration of morphine control. On the ordinate is
the cumulative WithdraWal signs Which are composed of unit
scores given that record the manifestation of characteristic

WithdraWal symptoms. Injection vehicle: saline.
FIG. 5 shoWs precipitated morphine WithdraWal With time
after the administration of M3A6S in the Rhesus monkey.

and

Precipitated WithdraWal test initiated by the injection of
M3A6S 2.5 hrs after an injection of morphine and animal

observed for signs of WithdraWal. All experimental condi
10

tions are similar to that in FIG. 4 except that the injection

vehicle is 25% TWeen in Water With gentle Warming.

FIG. 6 shoWs precipitated morphine WithdraWal With time
after the administration of DM3A6S in the Rhesus monkey.

wherein R1 may be a straight or branched chain alkyl or

alkenyl group having 1—5 carbon atoms;
Wherein R2 is an alkyl having 1—3 carbon atoms, and
Wherein R3 is H or n-alkyl or branched alkyl With 1—10

15

Precipitated WithdraWal test initiated by the injection of
DM3A6S 2.5 hrs after an injection of morphine and animal

carbon atoms, cycloalkyl, aralkyl, n-alkenyl or

observed for signs of WithdraWal. All experimental condi

branched alkenyl With 1—10 carbon atoms

tions are similar to that in FIG. 4.

(preferably 4—8 carbon atoms), and n-alkynyl or
branched alkynyl With 1—10 carbon atoms. R3 is

20

preferably selected from the group consisting of

OCH3, OCOCH3, OCOCH2CH3.

rat tail ?ick (RTF) assay. Dose of morphine and M65
administered: 0.0175 mmol/kg Wt. of animal/ml. Injection

The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

folloWing detailed description and ?gures, Wherein only the

vehicle: sesame seed oil, n=5. Time on the abscissa repre
25

preferred embodiments of the invention are shoWn and

described, simply by Way of illustration of the best mode of
carrying out the invention. As is readily recogniZed the
invention is capable of modi?cations Within the skill of the
relevant art Without departing from the spirit and scope of

FIG. 7 shoWs the analgesic pro?le of M65. Effect of
morphine 6-O-sulfate (M65) in comparison to morphine on
nociception after subcutaneous (s.c.) administration in the

sents time relative to morphine administration. Antinocice

ption is shoWn as the percent of maximum possible analge

sia (%MPA). Pre-drug response latencies (basal analgesia)
for morphine and M65 Were 2.01 and 2.23, respectively.
30

FIG. 8 shoWs the analgesic pro?le of M3A6S. Effect of

3-O-acetylmorphine-6-O-sulfate (M3A6S), in comparison

the invention.

to morphine, on nociception after so administration in the
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shoWs structures of morphine and morphine-6-O
sulfate derivatives.
FIG. 2 shoWs antinociceptive response to subcutaneous
treatment With morphine. Antinociception is shoWn as the
percent of maximum possible response in the tail-?ick test.
Free base morphine Was used for subcutaneous administra

tion (5 mg/kg, 0.0175 mmole) Equimolar doses of morphine

35

FIG. 9 shoWs the analgesic pro?le of M3Pr6S. Effect of

3-O-propionylmorphine-6-O-sulfate (M3Pr6S), in compari
son to morphine, on nociception after so administration in
40

derivatives Were as folloWs: M6S (6.4 mg/kg); M3A6S (7.1

mg/kg); M3B6S (8.2 mg/kg); and MM3A6S (7.4 mg/kg)
45

MM3A6S Were 2.15, 1.96, 2.37, 1.79, 1.95 and 2.11 seconds

respectively.

(as described in FIG. 7) except that for M3Ibu6S, n=4 and

saline vehicle, morphine and morphine derivatives. For

FIG. 11 shoWs analgesic pro?le of M3P6S Effect of

intracerebroventricular drug administration, 2 doses of mor

3-O-pivaloylmorphine-6-O-sulfate (M3P6S), in comparison

phine Were used; loW dose morphine (0.236 pig/rat, 0.83
pmole pmole/rat as free base) and high dose of morphine
(23.6 pig/rat, 83 pmole/rat). Doses of morphine derivatives

to morphine, on nociception after so administration in the

RTF assay. All experimental details remain the same (as
described in FIG. 7) except that for M3P6S, n=6 and the
basal analgesia value is 1.95.
55

pig/kg) ; M3A6S (0.25 pig/kg) ; M3B6S (0.29 pig/kg); and
MM3A6S (0.26 pig/kg). Antinociception is shoWn as the

to morphine, on nociception after so administration in the
60

Were 2.05, 2.06, 1.69, 1.92, 2.62, 2.06 and 1.82 seconds

respectively.
FIG. 4 shoWs precipitated morphine WithdraWal With time
after the administration of morphine in the Rhesus monkey.
Precipitated WithdraWal test initiated by injection of mor
phine control 2.5 hrs after an injection and animals observed
for signs of WithdraWal. Time on the abscissa represents time

FIG. 12 shoWs analgesic pro?le of M3B6S Effect of

3-O-benZoylmorphine-6-O-sulfate (M3B6S), in comparison

percent of maximum possible response in the tail-?ick test.

Predrug response latencies for saline, morphine loW dose,
morphine high dose, M6S, M3A6S, M3B6S, and MM3A6S

parison to morphine, on nociception after so administration
in the RTF assay. All experimental details remain the same

the basal analgesia value is 1.86.

FIG. 3 shoWs antinociceptive response to treatment With

administered intracerebroventricularly Were equimolar to
the loW dose of morphine and Were as folloWs: M6S (0.22

the RTF assay. All experimental details remain the same (as
described in FIG. 7) except that for M3Pr6S, n=3 and the
basal analgesia value is 1.97.

FIG. 10 shoWs the analgesic pro?le of M3Ibu6S Effect of
3-O-isobutyrylmorphine-6-O-sulfate (M3Ibu6S), in com

Were administered subcutaneously. Predrug response laten

cies for saline, morphine, M6S, M3A6S, M3B6S, and

RTF assay. All experimental details remain the same (as
described in FIG. 7) except that for M3A6S, n=4 and the
basal analgesia value is 1.77.

RTF assay. All experimental details remain the same (as
described in FIG. 7 except that for M3B6S, n=3 and the
basal analgesia value is 1.91.

FIG. 13 shoWs analgesic pro?le of DM3A6S Effect of

3-O-acetyl-7,8-dihydromorphine-6-O-sulfate (DM3A6S), in
65

comparison to morphine, on nociception after so adminis
tration in the RTF assay. All experimental details remain the
same (as described in FIG. 7) except that for DM3A6S, n=3
and the basal analgesia value is 1.90.

US 6,403,602 B1
6

5
FIG. 14 shows analgesic pro?le of DM3B6S Effect of

In vieW of the potent analgesia exhibited by the apparent

3-O-benZoyl-7,8-dihydromorphine-6-O-sulfate (DM3B6S),

structurallydissimilarmorphine-6-O-glucuronide (M6G) and
morphine-6-O-sulfate (M6S) conjugates of morphine, the

in comparison to morphine, on nociception after so admin
istration in the RTF assay. All experimental details remain

effect of structural modi?cation of M6S on analgesic activity
has been examined using the tail-?ick test. Changes in the

the same (as described in FIG. 7) except that for DM3B6S,
n=4 and the basal analgesia value is 1.78.
FIG. 15 shoWs analgesic pro?le of MM3A6S, Effect of

M6S structure Were made that Would affect the lipophilicity

and polarity of the molecule. Subcutaneous (sc) and intrac
erebroventricular (icv) administration of equimolar doses of

3-O-acetyl-N-methylmorphinium-6-O-sulfate (MM3A6S),
in comparison to morphine, on nociception after so admin
istration in the RTF assay. All experimental details remain
the same (as described in FIG. 7) except that for MM3A6S,
n=5 and the basal analgesia value is 2.03.

10

employed.

FIG. 16 shoWs analgesic pro?le of MM3B6S. Effect of

3-O-benZoyl-N-methylmorphinium-6-O-sulfate

morphine, M6S, 3-O-acetylmorphine-6-O-sulfate (M3A6S),
3-O-benZoylmorphine-6-O-sulfate (M3B6S) and 3-O
acetyl-N-methylmorphinium-6-O-sulfate (MM3A6S) Were

15

(MM3B6S), in comparison to morphine, on nociception
M6S and M3A6S unexpectedly exhibited a longer dura

after so administration in the RTF assay. All experimental

tion of action and greater activity compared to morphine

details remain the same (as described in FIG. 7) except that
for MM3B6S, n=4 and the basal analgesia value is 2.23.
20

DESCRIPTION OF THE INVENTION

addition, M3A6S shoWed the highest potency in inhibiting
electrically stimulated guinea pig ileum folloWed by M6S

The present invention relates to 3-O-Acetylmorphine-6
sulfate compounds and their ester derivatives Which are

potent, centrally-acting morphine derivatives. The com

after Sc and icv administration. HoWever, M3B6S and
MM3A6S in a doses equimolar to that of morphine Were
found to be inactive after both Sc and icv administration. In

and M3B6S. Moreover, both M6S and M3A6S displayed a
25

pounds are useful for the treatment of pain.

greater af?nity than that of morphine to mu and kappa3

receptor sites in guinea pig brain homogenate.

The folloWing is a list of abbreviations Which appear

throughout the application.
30

In contrast, the non-analgesic compounds M3B6S and

MM3A6S shoWed Weak receptor binding ability compared
CNS:

Central Nervous System

GI:

Gastrointestinal

PETT:
ATP:

Position emission transaxial tomography
5'—adenosine triphosphate

cAMP:

Cyclic 3',5'—adenosine monophosphate

MHP:

Mouse hot plate assay

UDPGA:
M6S:
M3A6S:
M3Pr6S:

Uridine diphosphate glucuronic acid
Morphine-6-O-sulfate
3-0—Acetylmorphine-6-O-sulfate
3-0-Propionylmorphine-6-O-sulfate

APS:

Adenosine 5 '-sulfatophosphate

PAPS:
M3P6S:
M3B6S:
DM3B6S:
M6G:
M3G:

3'—phosphoadenosine-5'—phosphosulfate
3-0-Pivaloylmorphine-6-0-sulfate
3-0-Benzoylmorphine-6-0-sulfate
3-0-Benzoyl-7,8-dihydromorphine-6-O-sulfate
Morphine-6-O-glucuronide
Morphine-3-O-glucuronide

35

40

i.c.v.:

Intracerebroventricular

i.p.:

Intraperitoneal

CSF:

Cerebro-spinal ?uid

DADL:

D-alanine D-leucine

DM:
DM6S:

7,8-Dihydromorphine
7,8-Dihydromorpihine-6-O-sulfate

MM3A6S:
MM3B6S:

3-0-Acetyl N-methylmorphinium-6-O-sulfate
3-0-Benzoyl N-methylmorphinium-6—O—sulfate

to morphine. These results indicate that lipophilicity alone is
not a determinant of analgesic activity in these novel mor
phine derivatives. These modi?ed effects of morphine by the
conjugations at the 3- and 6-position, appear to be due to
their altered interactions With opioid receptors

After examining the clinical activity of M6G in a group of
cancer patients, it has been concluded that the analgesic
effect of administered morphine is due mainly to metaboli

cally formed M6G rather than to morphine itself [11].

Interestingly, the conjugate, morphine-6-O-sulfate (M6S)
45

Was shoWn to exhibit more potent and longer acting anal

gesia than morphine itself in mice

On the other hand,

M6S shoWed comparatively reduced competing potencies
toWard mu-receptors but enhanced delta-receptor affinity

compared to parent compound morphine [10].

In vieW of the potent analgesia exhibited by the apparent
structurally dissimilar 6-O-glucuronide and 6-O-sulfate con
jugates of morphine, the effect of structural modi?cation on

s.c.:

Sub-cutaneous

TLC:

Thin Layer chromatography

HETCOR:
COSY:

Hetero-atom chemical shift correlation
Homonuclear correlation

DEPT:

Distortionless enhancement by polarization

antinociceptivity in the M6S molecule Was examined. Of

transfer

particular interest Was the effect of increasing lipophilicity
on activity by esteri?cation of the 3-hydroxy group and the
effect of increasing polarity by conversion of M6S to its

FABMS:
RTF:

Fast atom bombardment mass spectroscopy
Rat Tail Flick

% MPE:
% MPA:

Percentage of maximum possible effect
Percentage of maximum possible analgesia

SDA:

Single dose suppression

PPt-W:

Precipitated Withdrawal

CP/MAS:
SAR:

Cross polarization, magic angle spinning
Structure-activity relationship

TMS:
ADTN:

Tetramethyl silane
2-Amino-6,7-dihydroxytetrahydronaphthalene
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N-methyl morphinium betaine (see FIG. 1).
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As part of these structure-activity studies, the inventors
report on the potent, centrally-acting antinociceptive activity
of the morphine derivative, 3-O-acetylmorphine-6-O
sulfate, in the rat.

